Two NIDD patients discontinued the medication, one because of symptomatic postural hypotension and the other, who had a plasma creatinine level of 1.8 mg/dl, because of hyper-kalaemia (K = 6.1 mEq/L ). In the responders, enalapril did not alter glucose tolerance, plasma or urinary excretion...
We conducted a prospective, randomized, placebo-controlled trial to assess the safety of enalapril 5 mg during the early post-transplant period. Subjects took the study medication for six months. Primary endpoints were serum potassium (K) >5.9 mEq/L and 30% increase in baseline creatinine. A ...
Dietary potassium was also supplemented during the study diet weeks, given its crucial role in RAAS regulation, with 50 mEq of potassium chloride daily. Participants without P-HPT were given daily dietary calcium supplementation (1000 mg of calcium carbonate) to ensure similar intake between ...
InterventionsParticipants were randomly assigned to receive chlorthalidone, 12.5 to 25 mg/d (n = 15 255); amlodipine, 2.5 to 10 mg/d (n = 9048); or lisinopril, 10 to 40 mg/d (n = 9054) for planned follow-up of approximately 4 to 8 years. ...
Amiloride, at doses of 10-40 mg/day, increased mean plasma potassium levels in both primary hyperaldosteronism (3.2-4.5 mEq/L) and, to a lesser extent, in Bartter''s syndrome (2.5-3.6 mEq/L) The blood pressure fell slightly but significantly in primary hyperaldosteronism (171/112 vs 150/...
Two NIDD patients discontinued the medication, one because of symptomatic postural hypotension and the other, who had a plasma creatinine level of 1.8 mg/dl, because of hyper-kalaemia (K = 6.1 mEq/L ). In the responders, enalapril did not alter glucose tolerance, plasma or urinary excretion...
Study quality was high (median Jadad score 4).nnOutcomes: Medication discontinuation because of adverse effects, worsening renal function (increase in serum creatinine level > 0.5 mg/dL [44 mol/L]), hyperkalemia (serum potassium level >5.5 mEq/L [5.5 mmol/L]), and symptomatic hypotension.nnn...